As the KRAS p.G12C mutation is the most frequent variation among all KRAS mutations in NSCLC, presenting in 10–13% of patients with lung adenocarcinomas, the potentially effective therapies of KRAS p.G12C mutant NSCLC may help to optimize clinical treatment outcomes in this important and common subtype of lung cancers [63, 66]. Here, KRAS is linked to non-small cell lung carcinoma.